vimarsana.com
Home
Live Updates
China pharma must swallow that jagged little pill called R&D as government slashes profit margins of generic drugs : comparemela.com
China pharma must swallow that jagged little pill called R&D as government slashes profit margins of generic drugs
Beijing wants cheaper, better drugs. That’s pressuring drug makers to innovate as generics become more competitive.
Related Keywords
Japan ,
Shanghai ,
China ,
Ruilin ,
Jiangxi ,
Hong Kong ,
San Francisco ,
California ,
United States ,
Vancouver ,
British Columbia ,
Canada ,
New York ,
Boston ,
Massachusetts ,
Guoyuan ,
Shanxi ,
Houston ,
Texas ,
Peking ,
Beijing ,
Japanese ,
Chinese ,
Stephen Peepels ,
Lin Xiaowei ,
Ascletis Pharma ,
Michael Yu Dechao ,
Morgan Huang ,
Charles Li Xiaojia ,
Hogan Lovells ,
Huang Guobin ,
Innovent Biologics ,
Zai Lab ,
Jp Morgan Chase Co ,
Credit Suisse ,
Chinese Center ,
Nasdaq ,
Issuer Services Michael Chan ,
South China Morning Post ,
Research Development Association ,
Pharmaceutical Innovation ,
Song Ruilin ,
Guoyuan Securities ,
Hong Kong Listed ,
Hang Seng Mainland Healthcare Index ,
Everbright Securities ,
China Pharmaceutical Innovation ,
Houston Huang Guobin ,
Kong Exchanges ,
North America ,
Peking University ,
Disease Control ,
Biotech ,
Harmaceutical ,
Ipo ,
Kex ,
Generic ,
Healthcare ,
Dancer ,
comparemela.com © 2020. All Rights Reserved.